Literature DB >> 1985997

Use of autologous blood in total hip replacement. A comprehensive program.

S T Woolson1, J M Watt.   

Abstract

We evaluated the effectiveness of a comprehensive program for the use of autologous blood in reduction of the need for transfusion of homologous blood in total hip replacement in a prospective study of a consecutive series of patients. Transfusion of homologous blood was minimized through transfusion of preoperatively deposited autologous blood, intraoperative and postoperative salvage of washed red blood cells, and use of the clinical condition of the patient as the sole criterion for transfusion of non-autologous blood, regardless of the hematocrit. The cases of 143 patients who had had 154 primary total hip replacements were studied. One hundred and forty-three procedures were done on patients who had not been prevented from donating blood for medical reasons, and 93 per cent of these 143 procedures were performed with the availability of one to five units of preoperatively deposited autologous blood. The patients predeposited an average of 2.6 units of blood for each procedure. Ninety-two per cent of the procedures for which autologous blood had been predeposited were performed without transfusion of homologous blood. In the entire group of patients, almost 90 per cent of the transfused blood was autologous blood. Intraoperative salvage of red blood cells was successful in 148 procedures, and salvage was continued in the recovery room for all of these patients. An average of 408 milliliters of red blood cells was saved and reinfused, and this was 28 per cent of the average total loss of blood (1435 milliliters) for this series of procedures.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1985997

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  9 in total

Review 1.  Blood management and patient specific transfusion options in total joint replacement surgery.

Authors:  J J Callaghan; A I Spitzer
Journal:  Iowa Orthop J       Date:  2000

2.  Reducing the risk of allogeneic blood transfusion.

Authors:  Battista Borghi; Hanna van Oven
Journal:  CMAJ       Date:  2002-02-05       Impact factor: 8.262

3.  Alternative procedures for reducing allogeneic blood transfusion in elective orthopedic surgery.

Authors:  Kathrin Kleinert; Oliver M Theusinger; Johannes Nuernberg; Clément M L Werner
Journal:  HSS J       Date:  2010-01-28

4.  Allogenic blood transfusion following total hip arthroplasty: results from the nationwide inpatient sample, 2000 to 2009.

Authors:  Anas Saleh; Travis Small; Aiswarya Lekshmi Pillai Chandran Pillai; Nicholas K Schiltz; Alison K Klika; Wael K Barsoum
Journal:  J Bone Joint Surg Am       Date:  2014-09-17       Impact factor: 5.284

5.  Prospective randomised evaluation of a collagen/thrombin and autologous platelet haemostatic agent during cementless total hip arthroplasty.

Authors:  David M Joyce; Alison K Klika; Amar Mutnal; Viktor Krebs; Robert Molloy; Ulf Knothe; Wael K Barsoum
Journal:  Blood Transfus       Date:  2015-04-21       Impact factor: 3.443

6.  Blood transfusion practices in total joint arthroplasties in Jamaica.

Authors:  Re Christopher Rose; Ayana Crichlow; Christine Walters; Andrew Ameerally; Georgiana Gordon-Strachan
Journal:  J Clin Med Res       Date:  2009-12-28

7.  Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy in tertiary care hospitals of Jammu.

Authors:  Kumkum Sharma; Sumit B Sharma; Imran A Pukhta; Amit B Sharma; Abdul Q Salaria
Journal:  Asian J Transfus Sci       Date:  2013-01

8.  The use of clamped drainage to reduce blood loss in total hip arthroplasty.

Authors:  Jian-Gang Cao; Lei Wang; Jun Liu
Journal:  J Orthop Surg Res       Date:  2015-08-25       Impact factor: 2.359

9.  Bipolar sealer not superior to standard electrocautery in primary total hip arthroplasty: a meta-analysis.

Authors:  Yang Yang; Li-Chao Zhang; Fei Xu; Jia Li; Yong-Ming Lv
Journal:  J Orthop Surg Res       Date:  2014-10-10       Impact factor: 2.359

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.